A phase I, open-label, randomized crossover study to assess the effect of dosing of the MEK 1/2 inhibitor Selumetinib (AZD6244; ARRY-142866) in the presence and absence of food in patients with advanced solid tumors

✍ Scribed by Suzanne Leijen; Patricia M. M. B. Soetekouw; T. R. Jeffry Evans; Marianne Nicolson; Jan H. M. Schellens; Maria Learoyd; Lynda Grinsted; Victoria Zazulina; Thinn Pwint; Mark Middleton

• Publisher: Springer
• Year: 2011
• Tongue: English
• Weight: 303 KB
• Volume: 68
• Category: Article
• ISSN: 0344-5704
• DOI: 10.1007/s00280-011-1732-7